In a comprehensive life-cycle analysis, the climate protection partnership compared SkyCell 2500 and 1500 containers with a competitors’ conventional passive solutions, looking specifically at the transport of pharmaceutical products in the temperature range 2-8°C.
Experts at myclimate analysed the fuel consumption in air transport on typical routes to ascertain CO2 footprint of the containers, and also analsyed the emissions produced during the complete life-cycle of transport containers, from manufacturing through to decommissioning.
The results were definitive, says Dr Bettina Kahlert, Leader Resource Efficiency at myclimate. “… the big SkyCell 2500 container with a high interior transport volume performs best when looking at the entire life-cycle of the product and shipment, followed by the smaller SkyCell 1500.”
Nico Ross, CTO of SkyCell, commetned: “We initiated the study, because it has been our goal right from the start to develop and run the most efficient and safest pharma container system worldwide. We wanted to verify this from an independent and trustworthy source like myclimate.”
“From our analysis, we conclude that the CO2 emissions can be significantly reduced with containers that are optimisd for weight-volume ratio such as SkyCells,” says Kahlert. “It makes us proud that our work to develop the containers has paid off.”
“It is our mission to provide the most reliable and environmentally friendly transport solutions for temperature-sensitive shipments and the study by myclimate shows that we have achieved this,” said Richard Ettl, CEO of SkyCell. “We will keep improving our technology and services in order